banner
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna
@fgbonadonna.bsky.social
86 followers 530 following 38 posts
FGB promotes therapeutic innovation from the earliest phases of research and the education of new generations of physician-scientists in Oncology
Posts Media Videos Starter Packs
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · 1d
Camizestrant in association with abemaciclib, palbociclib or ribociclib shows a well-tolerated safety profile and encouraging clinical activity in heavily pretreated advanced breast cancer
fondazionebonadonna.org/en/camizestr...
#Oncology #CancerResearch
@mauriziocallari.bsky.social
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · 5d
Phost’in Therapeutics and Fondazione Gianni Bonadonna to present first clinical data on PhOx430, a First-In-Class GnT-V inhibitor, at @myesmo.bsky.social 2025. Press release fondazionebonadonna.org/wp-content/u...
#PhostInTherapeutics #FondazioneBonadonna #therapeuticinnovation #CancerResearch
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · 8d
Respiratory viral infections can lead to loss of the pro-dormancy phenotype in disseminated #BreastCancer cells in the lung, causing proliferation and expansion of carcinoma cells within days
fondazionebonadonna.org/en/metastati...
#FondazioneBonadonna #Oncology
@mauriziocallari.bsky.social
Metastatic breast cancer cells awakened by lung infections
Fondazione Gianni Bonadonna
fondazionebonadonna.org
2
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · 16d
The ATRACTIB phase 2 trial shows clinical benefit with a combination of atezolizumab, paclitaxel and bevacizumab as first-line treatment in advanced triple-negative breast cancer
fondazionebonadonna.org/en/atezolizu...
#FondazioneBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social
Atezolizumab, paclitaxel and bevacizumab as first line therapy in triple-negative breast cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
1
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · 23d
A dual HER2-targeted blockade with neoadjuvant pyrotinib and ARX788, a new antibody-drug conjugate, as a promising strategy in early or locally advanced HER2-positive breast cancer
fondazionebonadonna.org/en/pyrotinib...
#FondazioneBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social
Pyrotinib plus a new antibody-drug conjugate in HER+ breast cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
1
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · 28d
Milan to host the Joint Conference 2025 on New Drugs and the Impact of AI in Oncology, organized by FGB with the Prada Group as supporting partner, Fondazione Michelangelo and @ESOncology .
Press Release fondazionebonadonna.org/area-press/
#FondazioneGianniBonadonna #FondazioneMichelangelo
2
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Sep 8
SERENA-6 trial shows a longer progression-free survival with camizestrant added to a CDK4/6 inhibitor in advanced breast cancer with an ESR-1 mutation emerged during treatment fondazionemichelangelo.org/news-update/...
#FondazioneBonadonna #FondazioneMichelangelo #CancerResearch #Oncology
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Sep 1
MATTERHORN trial results show a significantly better event-free survival with perioperative durvalumab added to chemotherapy in resectable gastric or gastroesophageal junction adenocarcinoma
fondazionebonadonna.org/en/periopera...
#FondazioneBonadonna #CancerResearch @mauriziocallari.bsky.social
Perioperative durvalumab in gastric and gastroesophageal junction cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
1
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Aug 27
Final results from the IMpassion031 trial confirm that adding atezolizumab to neoadjuvant chemotherapy significantly improved clinical outcomes and cleared ctDNA at surgery
fondazionemichelangelo.org/news-update/...
#FondazioneMichelangelo #CancerResearch #Oncology
Peri-operative atezolizumab in early-stage triple-negative breast cancer - Fondazione Michelangelo
Final results from the IMpassion031 trial confirm that adding atezolizumab to neoadjuvant chemotherapy significantly improved clinical outcomes and cleared ctDNA at surgery
fondazionemichelangelo.org
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Aug 25
A phase 3 study shows clinical benefit for tarlatamab as second-line treatment after chemotherapy in patients with small-cell lung cancer
fondazionebonadonna.org/en/longer-su...
#fondazionemichelangelo #oncology #CancerResearch
@mauriziocallari.bsky.social
Longer survival with tarlatamab in small-cell lung cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Aug 6
In ER-positive, HER2-negative advanced breast cancer vepdegestrant led to significantly longer progression-free survival than fulvestrant in the subgroup with ESR1 mutations
www.fondazionemichelangelo.org/news-update/...
#fondazionemichelangelo #oncology #CancerResearch
The PROTAC estrogen receptor degrader vepdegestrant in advanced breast cancer - Fondazione Michelangelo
In ER-positive, HER2-negative advanced breast cancer vepdegestrant led to significantly longer progression-free survival than fulvestrant in the subgroup with ESR1 mutations
www.fondazionemichelangelo.org
1
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Aug 4
Trastuzumab deruxtecan led to significantly longer overall survival than ramucirumab plus paclitaxel among patients with HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma
fondazionebonadonna.org/en/trastuzum...
#FondazioneBonadonna #Oncology #CancerResearch
Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
1
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Jul 30
“Online the Scientific Programme of the FGB-FM-ESO Joint International Conference 2025 “INNOVATION IN ONCOLOGY: New Drugs and the Impact of Artificial Intelligence”. Read more and register online at www.eso.net/en/what-we-d...
1
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Jul 29
Adjuvant cemiplimab led to to longer disease-free survival than placebo in cutaneous squamous-cell carcinoma with a high risk for recurrence
fondazionebonadonna.org/en/cemiplima...

#FondazioneBonadonna #Oncology #CancerResearch

@mauriziocallari.bsky.social
Cemiplimab in high risk cutaneous squamous-cell carcinoma
Fondazione Gianni Bonadonna
fondazionebonadonna.org
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Jul 22
Addition of pembrolizumab to enzalutamide and androgen deprivation therapy is not effective in metastatic hormone-sensitive prostate cancer
fondazionebonadonna.org/en/pembroliz...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social
Pembrolizumab plus enzalutamide and androgen deprivation therapy in prostate cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Jul 16
Sunday July 20th is the deadline for submitting applications for the “Fellowship Gianni Bonadonna” ed 25 – Read more fondazionebonadonna.org/en/fellowshi...

Il 20 luglio scadono i termini per inviare la candidature per la “Fellowship Gianni Bonadonna” 25 - Leggi fondazionebonadonna.org/fellowship/
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Jul 14
Inavosilib plus palbociclib-fulvestrant led to a significant survival benefit versus placebo plus palbociclib-fulvestrant in PIK3CA-mutated advanced breast cancer
fondazionebonadonna.org/en/inavosili...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Inavosilib in PIK3CA-mutated advanced breast cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Jul 7
A first-line treatment with alectinib plus bevacizumab show efficacy and safety in ALK-rearranged non-small cell lung cancer
fondazionebonadonna.org/en/alectinib...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Alectinib plus bevacizumab in ALK-rearranged non-small cell lung cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Jun 30
Nivolumab plus low-dose ipilimumab shows good response rate and a clinical benefit in hypermutated HER2-negative metastatic breast cancer
fondazionebonadonna.org/en/nivolumab...
#fondazionebonadonna #oncology #CancerResearch
@mauriziocallari.bsky.social
Nivolumab and low-dose ipilimumab in HER2-negative metastatic breast cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Jun 23
Trastuzumab rezetecan showed robust activity with a tolerable safety profile in a neoadjuvant setting in HER2-positive breast cancer
fondazionebonadonna.org/trastuzumab-...
#fondazionebonadonna #Oncology #breastcancer @mauriziocallari.bsky.social
Trastuzumab rezetecan in terapia neoadiuvante nel carcinoma mammario HER2+
Fondazione Gianni Bonadonna
fondazionebonadonna.org
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Jun 16
First line treatment with tremelimumab plus durvalumab and chemotherapy improved clinical outcomes in non-small-cell lung cancer with high or low, tissue or blood tumor mutational burden
fondazionebonadonna.org/en/durvaluma...
#fondazionebonadonna #CancerResearch @mauriziocallari.bsky.social
Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · Jun 10
Clinically meaningful activity and manageable safety for trastuzumab rezetecan in advanced, previously treated HER2mutant non small-cell lung cancer
fondazionebonadonna.org/en/trastuzum...
#fondazionebonadonna #oncology #CancerResearch @mauriziocallari.bsky.social
Trastuzumab rezetecan in advanced HER2-mutant non small-cell lung cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
2
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · May 28
Avoidance of breast surgery after neoadjuvant systemic therapy may be feasible in selected invasive breast cancer patients
fondazionemichelangelo.org/news-update/...
#fondazionemichelangelo #CancerResearch #Oncology
@mauriziocallari.bsky.social
Selective elimination of breast surgery in invasive breast cancer - Fondazione Michelangelo
A new nonrandomized clinical trial shows that avoidance of breast surgery after neoadjuvant systemic therapy may be feasible in selected patients
fondazionemichelangelo.org
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · May 26
Fondazione Gianni Bonadonna, with #PradaGroup as supporting partner, announces the edition 2025 of the post-doctoral Fellowship Program in collaboration with the #ESOncology Applications open from June 3rd until July 20th.
#fondazionebonadonna #fellowship
fondazionebonadonna.org/en/a-new-edi...
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna @fgbonadonna.bsky.social · May 19
Afami-cel showed durable responses in heavily pretreated patients with sarcoma, providing a rationale for the treatment of solid tumors with a T-cell receptor therapy
fondazionebonadonna.org/en/afamitres...
#fondazionebonadonna #oncology #CancerResearch
@mauriziocallari.bsky.social
Afamitresgene autoleucel in advanced synovial sarcoma and myxoid round cell liposarcoma
Fondazione Gianni Bonadonna
fondazionebonadonna.org
1 1